Qiagen (NYSE:QGEN – Get Free Report) released its quarterly earnings data on Wednesday. The company reported $0.65 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.63 by $0.02, Zacks reports. Qiagen had a return on equity of 14.47% and a net margin of 19.49%. During the same quarter last year, the company earned $0.61 earnings per share. The firm’s quarterly revenue was up 2.8% on a year-over-year basis.
Qiagen Price Performance
NYSE QGEN traded up $0.44 during trading hours on Wednesday, reaching $50.82. 3,228,032 shares of the company’s stock were exchanged, compared to its average volume of 5,863,858. The stock has a market cap of $10.47 billion, a PE ratio of 20.80, a price-to-earnings-growth ratio of 5.01 and a beta of 0.56. Qiagen has a one year low of $32.53 and a one year high of $57.81. The firm has a fifty day moving average of $45.55 and a 200-day moving average of $42.77. The company has a current ratio of 2.85, a quick ratio of 2.31 and a debt-to-equity ratio of 0.48.
Wall Street Analyst Weigh In
A number of research analysts have issued reports on the company. Citigroup restated a “neutral” rating and issued a $52.00 target price (up from $45.00) on shares of Qiagen in a research note on Monday, October 26th. Berenberg Bank set a $45.50 target price on shares of Qiagen and gave the stock a “hold” rating in a report on Tuesday, July 14th. JPMorgan Chase & Co. cut shares of Qiagen from an “overweight” rating to a “neutral” rating and dropped their target price for the stock from $55.00 to $52.00 in a research report on Thursday, October 22nd. TD Cowen reiterated a “hold” rating on shares of Qiagen in a research report on Wednesday, July 15th. Finally, Morgan Stanley reissued an “overweight” rating on shares of Qiagen in a report on Friday, September 11th. Four equities research analysts have rated the stock with a Buy rating and eleven have assigned a Hold rating to the company. According to MarketBeat.com, the company has an average rating of “Hold” and an average price target of $46.09.
About Qiagen
QIAGEN N.V. (NYSE:QGEN) is a global provider of sample preparation technologies, molecular testing solutions and bioinformatics for the life sciences and molecular diagnostics markets. The company develops products that help researchers and clinical laboratories isolate, analyze and interpret DNA, RNA and other biological materials.
Its portfolio includes sample collection and purification kits, automated laboratory instruments, PCR and next-generation sequencing assays, digital PCR solutions, bioinformatics software and related consumables.
See Also
- Five stocks we like better than Qiagen
- Why ExxonMobil and Chevron Reminded Investors to Keep it Simple
- Amazon Has Erased Its Earnings Sell-Off, But Is the Biggest Opportunity Still Ahead?
- onsemi’s AI Sales Surge 175%: Is a Stock Recovery Next?
- Energy Transfer’s Earnings Miss May Be Hiding Its Strongest Advantage
Receive News & Ratings for Qiagen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Qiagen and related companies with MarketBeat.com's FREE daily email newsletter.
